基于“阳化气,阴成形”理论解析桥本甲状腺炎的免疫微环境失衡
Elucidating Immune Microenvironment Dysregulation in Hashimoto’s Thyroiditis Based on the Theory of “Yang Transforming Qi and Yin Forming Substance”
DOI: 10.12677/tcm.2026.153165, PDF,    科研立项经费支持
作者: 李林峰:成都中医药大学临床医学院,四川 成都;高 泓*:成都中医药大学附属医院内分泌科,四川 成都
关键词: 桥本甲状腺炎免疫微环境阳化气阴成形中医药干预Hashimoto’s Thyroiditis Immune Microenvironment Yang Transforming Qi Yin Forming Substance Traditional Chinese Medicine Intervention
摘要: 桥本甲状腺炎是常见的自身免疫性甲状腺疾病,以淋巴细胞浸润、自身抗体阳性及甲减为特征。基于“阳化气,阴成形”理论解析其免疫微环境失衡,将“阳化气”对应于调节性T细胞介导的免疫耐受等动态功能,“阴成形”对应于淋巴细胞浸润、自身抗体沉积及纤维化等病理结构。该病免疫失衡可阐释为“阳化气不足”与“阴成形太过”:前者表现为调节性T细胞功能衰竭,后者表现为辅助性T细胞17异常增殖及纤维化。脾肾阳虚、气化失司为本,导致痰瘀互结形成标实,二者互为因果,形成“阳虚阴凝”的恶性循环。本研究从阴阳失衡角度揭示了该病从功能衰退到结构异化的病机演变规律,为“扶阳化气、祛痰化瘀”法干预提供了理论依据。
Abstract: Hashimoto’s thyroiditis is a common autoimmune thyroid disease characterized by lymphocytic infiltration, autoantibody positivity, and hypothyroidism. Based on the theory of Yang Transforming Qi and Yin Forming Substance, this study analyzes the immune microenvironment imbalance, correlating “Yang transforming Qi” with dynamic functions such as regulatory T cell-mediated immune tolerance, and “Yin forming substance” with pathological structures including lymphocytic infiltration, autoantibody deposition, and fibrosis. The immune imbalance can be interpreted as a disharmony between “insufficiency of Yang transforming Qi” and “excess of Yin forming substance”: the former manifests as regulatory T cell dysfunction, while the latter presents as abnormal T helper 17 cell proliferation and thyroid fibrosis. Spleen-kidney Yang deficiency and dysfunction of Qi transformation constitute the root cause, leading to the intermingling of phlegm and blood stasis as the branch manifestation; these two aspects interact as cause and effect, creating a vicious cycle of “Yang deficiency with Yin congelation”. This study elucidates the pathological evolution from functional decline to structural alienation through the perspective of Yin-Yang imbalance, providing a theoretical basis for clinical intervention using the therapeutic principles of “supporting Yang to transform Qi and dispelling phlegm to resolve stasis”.
文章引用:李林峰, 高泓. 基于“阳化气,阴成形”理论解析桥本甲状腺炎的免疫微环境失衡[J]. 中医学, 2026, 15(3): 268-275. https://doi.org/10.12677/tcm.2026.153165

参考文献

[1] Hu, X., Chen, Y., Shen, Y., Tian, R., Sheng, Y. and Que, H. (2022) Global Prevalence and Epidemiological Trends of Hashimoto’s Thyroiditis in Adults: A Systematic Review and Meta-Analysis. Frontiers in Public Health, 10, Article ID: 1020709. [Google Scholar] [CrossRef] [PubMed]
[2] Zhang, Q., Ye, X., Zhou, Z., Zhu, C., Li, R., Fang, Y., et al. (2022) Lymphocyte Infiltration and Thyrocyte Destruction Are Driven by Stromal and Immune Cell Components in Hashimoto’s Thyroiditis. Nature Communications, 13, Article No. 775. [Google Scholar] [CrossRef] [PubMed]
[3] Ralli, M., Angeletti, D., Fiore, M., D’Aguanno, V., Lambiase, A., Artico, M., et al. (2020) Hashimoto’s Thyroiditis: An Update on Pathogenic Mechanisms, Diagnostic Protocols, Therapeutic Strategies, and Potential Malignant Transformation. Autoimmunity Reviews, 19, Article ID: 102649. [Google Scholar] [CrossRef] [PubMed]
[4] Huang, S., Ziros, P.G., Chartoumpekis, D.V., Psarias, G., Duntas, L., Zuo, X., et al. (2024) Traditional Chinese Medicine for Hashimoto’s Thyroiditis: Focus on Selenium and Antioxidant Phytochemicals. Antioxidants, 13, Article No. 868. [Google Scholar] [CrossRef] [PubMed]
[5] Lebiedziński, F. and Lisowska, K.A. (2023) Impact of Vitamin D on Immunopathology of Hashimoto’s Thyroiditis: From Theory to Practice. Nutrients, 15, Article No. 3174. [Google Scholar] [CrossRef] [PubMed]
[6] Peng, X., Zhu, X., Di, T., Tang, F., Guo, X., Liu, Y., et al. (2022) The Yin-Yang of Immunity: Immune Dysregulation in Myelodysplastic Syndrome with Different Risk Stratification. Frontiers in Immunology, 13, Article ID: 994053. [Google Scholar] [CrossRef] [PubMed]
[7] Nanba, T., Watanabe, M., Inoue, N. and Iwatani, Y. (2009) Increases of the Th1/Th2 Cell Ratio in Severe Hashimoto’s Disease and in the Proportion of Th17 Cells in Intractable Graves’ Disease. Thyroid, 19, 495-501. [Google Scholar] [CrossRef] [PubMed]
[8] 雒毅强. Th1、Th2细胞及相关细胞因子在桥本甲状腺炎和甲状腺乳头状癌中差异性表达的初步研究[D]: [硕士学位论文]. 长春: 吉林大学, 2017.
[9] Jadali, Z., Esfahanian, F., Ghelich, R. and Rashidian, H. (2017) Increased Levels of Serum Interleukin-17 in Patients with Hashimoto’s Thyroiditis. Indian Journal of Endocrinology and Metabolism, 21, Article No. 551. [Google Scholar] [CrossRef] [PubMed]
[10] 王新, 范芝俏, 范丹, 等. 桥本甲状腺炎患者血清miR-326、miR-155与甲状腺相关抗体和Th17/Treg细胞因子失衡的相关性分析[J]. 现代生物医学进展, 2023, 23(23): 4501-4505.
[11] Zaletel, K. and Gaberscek, S. (2011) Hashimotos Thyroiditis: From Genes to the Disease. Current Genomics, 12, 576-588. [Google Scholar] [CrossRef] [PubMed]
[12] 肖艳琪, 裴瑞霞, 郑艳, 等. 中医药干预桥本甲状腺炎相关信号通路研究进展[J]. 中国实验方剂学杂志, 2025, 31(23): 237-247.
[13] Li, C., Yuan, J., Zhu, Y., Yang, X., Wang, Q., Xu, J., et al. (2016) Imbalance of Th17/Treg in Different Subtypes of Autoimmune Thyroid Diseases. Cellular Physiology and Biochemistry, 40, 245-252. [Google Scholar] [CrossRef] [PubMed]
[14] 程极, 于磊, 裴晓艳, 等. GARP、Foxp3及TGF-β在桥本甲状腺炎病人PBMC中的表达及意义[J]. 蚌埠医学院学报, 2024, 49(1): 55-58.
[15] Vitales-Noyola, M., Serrano-Somavilla, A., Martínez-Hernández, R., Sampedro-Nuñez, M., Ramos-Levi, A.M., González-Amaro, R., et al. (2018) Patients with Autoimmune Thyroiditis Show Diminished Levels and Defective Suppressive Function of Tr1 Regulatory Lymphocytes. The Journal of Clinical Endocrinology & Metabolism, 103, 3359-3367. [Google Scholar] [CrossRef] [PubMed]
[16] Luo, T., Zhao, X., Jiang, X., Li, P., Gu, X., Xie, X., et al. (2025) Serum Metabolomic Analysis in Patients with Hashimoto’s Thyroiditis Positive for TgAb or TPOAb: A Preliminary Study. Scientific Reports, 15, Article No. 9945. [Google Scholar] [CrossRef] [PubMed]
[17] Mohr, A., Trésallet, C., Monot, N., Bauvois, A., Abiven, D., Atif, M., et al. (2020) Tissue Infiltrating LTi-Like Group 3 Innate Lymphoid Cells and T Follicular Helper Cells in Graves’ and Hashimoto’s Thyroiditis. Frontiers in Immunology, 11, Article No. 601. [Google Scholar] [CrossRef] [PubMed]
[18] Wang, Y., Yan, Z., Miao, J., Que, H. and Shan, W. (2025) Research Progress of Natural Killer Cells in Hashimoto’s Thyroiditis. ImmunoTargets and Therapy, 14, 1029-1040. [Google Scholar] [CrossRef
[19] 吴菲, 许铖铖, 郑婷婷, 等. IFN-γ通过激活STAT3促进甲状腺上皮细胞分泌CXC趋化因子配体10(CXCL10) [J]. 细胞与分子免疫学杂志, 2017, 33(6): 811-814+819.
[20] 孙庆凯, 陈占玲, 李春华, 等. 白细胞介素6/转化生长因子-β信号异常在桥本甲状腺炎辅助性T细胞17/调节性T细胞失衡中的作用研究[J]. 中华内分泌代谢杂志, 2015, 31(4): 320-326.
[21] 俞洋, 张金艳, 魏皓月, 等. 四逆消瘿方抑制STAT3棕榈酰化调控Th17/Treg平衡改善桥本甲状腺炎[J]. 上海中医药杂志, 2025, 59(9): 75-84.
[22] Uccella, S., Dottermusch, M., Erickson, L., Warmbier, J., Montone, K. and Saeger, W. (2023) Inflammatory and Infectious Disorders in Endocrine Pathology. Endocrine Pathology, 34, 406-436. [Google Scholar] [CrossRef] [PubMed]
[23] Li, G., He, L., Huang, J., Liu, J., Chen, W., Zhong, J., et al. (2023) miR-142-3p Encapsulated in T Lymphocyte-Derived Tissue Small Extracellular Vesicles Induces Treg Function Defect and Thyrocyte Destruction in Hashimoto’s Thyroiditis. BMC Medicine, 21, Article No. 206. [Google Scholar] [CrossRef] [PubMed]
[24] 彭晓芳, 于佳乐, 巴帅杰, 等. 基于温肾健脾法调节甲状腺-肠轴治疗桥本甲状腺炎[J]. 山西中医药大学学报, 2025, 26(9): 1003-1008.
[25] 王欢, 何其函, 李思思, 等. 从脾论治桥本甲状腺炎[J]. 西部中医药, 2023, 36(8): 45-48.
[26] 牛洋, 张慧艳, 邓斌, 等. 桥本甲状腺炎的中西医治疗研究进展[J]. 医学信息, 2025, 38(2): 188-192.
[27] 李世霞, 张旭辉, 李红梅, 等. 基于“久病入络”理论探讨“虚” “痰” “瘀”与肺纤维化的关系[J]. 实用中医内科杂志, 2024, 38(5): 28-30.
[28] 王卫群, 马丽. 甲状腺腺瘤从痰瘀论治28例分析[J]. 新疆中医药, 2007, 25(6): 16-17.
[29] 王昭, 彭书旺, 王永恒. 彭坚基于“痰瘀互结”理论治疗甲状腺结节经验[J]. 中医药导报, 2023, 29(3): 206-209.
[30] 陈晔欣, 林茂炫, 高子衡, 等. 运用养阴调阳法分期辨治桥本甲状腺炎临证经验[J]. 环球中医药, 2026, 19(1): 114-119.
[31] 甘双双, 邵迎新, 谭爱华. 基于“阳化气, 阴成形”理论辨治桥本甲状腺炎验案举隅[J]. 中国民族民间医药, 2024, 33(4): 84-86.
[32] 吴倩, 倪青. 以通为用论治桥本氏甲状腺炎[J]. 环球中医药, 2020, 13(6): 1087-1089.
[33] 武鹏达, 肖诚浦, 张东帅, 等. 姜德友从“郁、结、虚”分期辨治桥本甲状腺炎经验[J/OL]. 时珍国医国药, 1-7.
https://link.cnki.net/urlid/42.1436.R.20260127.1455.005, 2026-02-23.
[34] 李艳, 赵海军, 王春莉, 等. 消瘿汤加减治疗桥本甲状腺炎伴甲减患者疗效及对甲状腺自身抗体和免疫功能的影响[J]. 现代中西医结合杂志, 2025, 34(5): 657-661.
[35] 武文平, 张薇, 佟瑞. 健脾温肾正气法治疗脾肾阳虚型桥本甲状腺炎的效果及对甲状腺功能的影响[J]. 辽宁中医杂志, 2025, 52(6): 59-62.
[36] 吴春丽, 郭奉琳, 秦美灵, 等. 温阳消瘿方治疗桥本甲状腺炎临床疗效及对患者TPOAb、TGAb抗体滴度的影响[J]. 实用中医内科杂志, 2024, 38(2): 31-34.
[37] 姜丽丽. 右归丸加减治疗桥本氏甲状腺炎(脾肾阳虚, 痰瘀阻络证)的临床观察[D]: [硕士学位论文]. 吉林: 长春中医药大学, 2017.
[38] 陈婧, 戴欣珏, 车名花, 等. 解郁通络消瘿汤联合常规西医治疗桥本甲状腺炎的临床研究[J]. 辽宁中医杂志, 2024, 51(6): 82-85.
[39] 曾炜美, 王舢泽, 王冠群, 等. 针刺手足阳明经穴治疗桥本甲状腺炎30例临床观察[J]. 中医杂志, 2023, 64(15): 1550-1555.
[40] 张丹. 温阳化痰法治疗桥本氏甲状腺炎的临床疗效及对IL-6水平的影响[D]: [硕士学位论文]. 济南: 山东中医药大学, 2015.
[41] 刘涵. 左甲状腺素钠对TPOAb阳性亚临床甲状腺功能减退孕妇的干预研究[J]. 医药论坛杂志, 2021, 42(16): 64-67.
[42] 邓洪枭, 司新颖, 魏光成, 等. 基于整合证据链评价9种常用中成药治疗桥本甲状腺炎证据等级及思考[J/OL]. 中国全科医学, 1-9.
https://link.cnki.net/urlid/13.1222.R.20251215.0907.004, 2026-03-04.
[43] 刘佳琳, 王鑫蕊, 秦伟璇, 等. 六种中成药联合左甲状腺素钠治疗桥本甲状腺炎的网状Meta分析[J]. 中医临床研究, 2025, 17(22): 51-62.
[44] 李鸣, 付黎韵, 闫凯, 等. 基于网络药理学及分子对接技术研究夏枯草-猫爪草药对治疗桥本氏甲状腺炎的药效物质基础及作用机制[J]. 甘肃中医药大学学报, 2024, 41(2): 55-61.
[45] 唐柱生. 头颈部危险穴位针刺安全深度的MRI和尸体对照研究[D]: [硕士学位论文]. 昆明: 云南中医学院, 2012.
[46] Otsuji, K., Tanabe, M., Morizono, A., et al. (2023) Exploring Predictive Risk Factors of Infusion Reactions with First Pertuzumab Administration in HER2-Positive Breast Cancer Patients: A Single Institution Experience. JMA Journal, 6, 63-72.
[47] Wang, S., Zhao, J., Zeng, W., Du, W., Zhong, T., Gao, H., et al. (2021) Acupuncture for Hashimoto Thyroiditis: Study Protocol for a Randomized Controlled Trial. Trials, 22, Article No. 74. [Google Scholar] [CrossRef] [PubMed]